Cas:75948-77-5 4,6-Dimethylindole manufacturer & supplier

Chemical Name:4,6-Dimethylindole

CAS.NO:75948-77-5

Synonyms:4,6-Dimethylindole;1H-indole, 4,6-dimethyl-;1H-Indole,4,6-dimethyl;4,6-Dimethyl-indol;4,6-Dimethyl-1H-indole

Molecular Formula:C₁₀H₁₁N

Molecular Weight:145.201

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:275.3±9.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.636

PSA:15.79000

Exact Mass:145.089142

LogP:3.06

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4,6-Dimethylindole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4,6-Dimethyl-1H-indole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4,6-Dimethylindole Use and application,4,6-Dimethyl-indol technical grade,usp/ep/jp grade.

Related News: Multinational drugmakers usually cut the price of drugs when they go off-patent and face competition from generic versions, but such price drops were slow to happen in China, partially because many local drugmakers were unable to develop high-quality generic drugs to compete with off-patent branded drugs. 4,6-Dimethylindole manufacturer Novak noted that the research team did see some improvement in standard brain function tests given to a smaller group of trial participants who had actually been diagnosed with Alzheimer’s. 4,6-Dimethylindole supplier Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm. 4,6-Dimethylindole vendor Prime Minister Scott Morrison said Saturday that all travelers from mainland China allowed into Australia had to be quarantined for 14 days. 4,6-Dimethylindole factory Multinational drugmakers usually cut the price of drugs when they go off-patent and face competition from generic versions, but such price drops were slow to happen in China, partially because many local drugmakers were unable to develop high-quality generic drugs to compete with off-patent branded drugs.